NCT06285253 - miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Acute Liver FailureAcute Liver Injury, Drug InducedAcute on Chronic Liver Failure (ACLF)Acute Alcoholic Hepatitis

Interventions

COMBINATION_PRODUCT

miroliverELAP treatment

Subject's blood will be perfused through a bioengineered liver graft via an extracorporeal blood circuit.

Trial Locations (8)

RECRUITING

Mount Sinai Recanati/Miller Transplantation Institute, New York

RECRUITING

Virginia Commonwealth University Medical Center, Richmond

RECRUITING

Cleveland Clinic Foundation, Cleveland

RECRUITING

University of Michigan Medical School, Ann Arbor

RECRUITING

University of Minnesota Medical School, Minneapolis

RECRUITING

Mayo Clinic, Rochester

RECRUITING

Northwestern Memorial Hospital, Chicago

RECRUITING

Intermountain Healthcare, Salt Lake City